Share

By Date


  • 10-June-2020

    English

    Anti-Bribery Responses to COVID-19

    The COVID-19 crisis is affecting the fight against bribery and corruption. This page groups responses that can help guide the actions of governments and other actors in today's challenging times.

    Related Documents
  • 22-May-2020

    English

    OECD Global Anti-Corruption & Integrity Forum: Webinar Series

    These webinars bring together experts from the public, private and civil society sectors to share knowledge and debate issues relating to anti-corruption and integrity. Sign up to attend forthcoming webinars or view past webinars.

    Related Documents
  • 20-May-2020

    English

    COVID-19 is a chilling reminder of why the world needs to protect whistleblowers

    OECD’s Leah Ambler and Apostolos Zampounidis underline why whistleblower protection plays such a critical role in the fight against bribery and corruption in the run-up to an OECD webinar on “Emergency measures to protect whistleblowers and promote reporting during the COVID-19 crisis and beyond”.

    Related Documents
  • 20-May-2020

    English

    OECD Public Integrity Handbook

    The OECD Public Integrity Handbook provides guidance to government, business and civil society on implementing the OECD Recommendation on Public Integrity. The Handbook clarifies what the Recommendation’s thirteen principles mean in practice and identifies challenges in implementing them. The Handbook provides guidance on improving co-operation within government, as well between the national and subnational levels. To build cultures of integrity across government and society, the Handbook details the core elements of a merit-based human resource management system and the key ingredients of open organisational cultures. It also clarifies government’s role in providing guidance to companies, civil society and citizens on upholding public integrity values. Moreover, the Handbook unpacks how to use the risk management process to assess and manage integrity risks, and highlights how to use the enforcement system to ensure real accountability for integrity violations.
    Also AvailableEgalement disponible(s)
  • 19-May-2020

    English

    2020 Global Forum on Responsible Business Conduct

    19 May 2020: The 2020 Global Forum will be held virtually and in two parts. The first part on 19 May 2020 will focus on how governments and businesses can use an responsible business conduct approach to address the COVID-19 crisis and build more resilient supply chains.

    Related Documents
  • 14-May-2020

    English

    OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions

    This page gives you access to the OECD Anti-Bribery Convention and related instruments (Commentaries on the Convention, 2009 Revised Recommendation, 2009 Recommendation on Tax Deductibility of Bribes, and other related instruments).

    Related Documents
  • 14-May-2020

    English

    Country monitoring of the OECD Anti-Bribery Convention

    Countries’ implementation and enforcement of the OECD Anti-Bribery Convention is monitored by the OECD Working Group on Bribery through a rigorous peer-review monitoring system, which Transparency International calls the “gold standard” of monitoring.

    Related Documents
  • 22-April-2020

    English

    The global response to the coronavirus pandemic must not be undermined by bribery

    In the face of the coronavirus outbreak, the OECD Working Group on Bribery reaffirms its collective commitment to fight foreign bribery under the Anti-Bribery Convention.

    Related Documents
  • 24-March-2020

    English

    2020 Roundtable on Anti-Corruption and Business Integrity

    2020 Roundtable on Anti-Corruption and Business Integrity will take place during OECD Integrity Week at the OECD Conference Centre on 24th March 2020.

    Related Documents
  • 23-March-2020

    English

    Trade in Counterfeit Pharmaceutical Products

    This report, one in a series of studies by the OECD and the European Union Intellectual Property Office (EUIPO), enhances understanding of the issues and challenges facing governments, businesses and society posed by the trade in fake pharmaceutical products. Illicit markets for fake pharmaceuticals are attractive for counterfeiters, given the high profit margins, low risks of detection and prosecution, weak penalties, and the ease with which consumers can be deceived into believing that the counterfeit products are genuine. Counterfeit medicines not only cause economic damage for the sector, but are also a significant threat to public health, since fake medicines are often not properly formulated and may contain dangerous ingredients. Fake pharmaceuticals include antibiotics, lifestyle treatments, pain killers, anti-malarial drugs, diabetes treatments and central nervous system medicines.
  • << < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>